Belite Bio Unveils Plan to Offer 651,380 American Depository Shares

Belite Bio (BLTE) said late Thursday it is planning to sell up to 651,380 American depositary shares at $38.38 per ADS in a registered direct offering. The company also plans to sell warrants to purch

MT Newswires18:21

Belite Bio Prices $25M Direct Offering

Seeking Alpha17:02

Reported Earlier, Belite Bio Secures $25M In Registered Direct Offering With Institutional Investors

Belite Bio entered into a securities purchase agreement with an institutional investor, for the purchase and sale of up to an aggregate of 651,380 American Depositary Shares of the Company ("ADSs"), e

Benzinga15:03

Belite Bio Announces $25 Million Registered Direct Offering

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting

GlobeNewswire07:15

Belite Bio Is Maintained at Buy by HC Wainwright & Co.

Belite Bio Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 22 23:23

HC Wainwright & Co. Maintains Buy on Belite Bio, Maintains $59 Price Target

HC Wainwright & Co. analyst Yi Chen maintains Belite Bio with a Buy and maintains $59 price target.

Analyst UpgradesMar 22 23:13